Crossmark

Progression of peripheral blood mononuclear cell mitochondrial function during the early phase of sepsis in intensive care unit patients

Published Online: 2026-02-13

Authors

Moonen, Hanneke P. F. X.

Slingerland-Boot, Rianne

de Jong, Jelle C. B. C.

Wiech, Anaïs M. T. Y.

Nieuwenhuizen, Arie G.

Grefte, Sander

van Zanten, Arthur R. H.
Funding

Funding for this research was provided by:

Research Foundation of the Intensive Care of Gelderse Vallei Hospital, Ede, The Netherlands
License Information

Text and Data Mining valid from 2026-02-13

Accepted Manuscript valid from 2026-02-13
More Information

Article History

Received: 11 December 2025

Accepted: 3 February 2026

First Online: 13 February 2026

Declarations

:

: Prof. Dr. Van Zanten reported receiving honoraria for advisory board meetings, lectures, research grants, and travel expenses from Abbott, AOP Pharma, Baxter, Danone-Nutricia, Dutch Medical Food, Fresenius Kabi, GE Healthcare, Medcaptain, Nestle, PAION and Rousselot. The other authors have nothing to declare.

: The study was approved by the Medical Ethical Committee of Wageningen University (METC-WUR, which was incorporated in the METC Oost-Nederland in 2021, dossier no. 2021–13011) and the assessment Committee for Scientific Research of ZGV (dossier no. 1801–004). The protocol was registered in the Netherlands Trial Register (number NTR6969) and was made available through the International Clinical Trial Registry Platform (NL5918). Patients were enrolled after signing the informed consent by the patient or legal representative.

: Not applicable.

Document is current